Cytokinetics, Incorporated
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert I. Blum
- Full Time Employees
- 673
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 350 Oyster Point Boulevard South San Francisco CA United States 94080
- IPO Date
- Apr 29, 2004
- CIK
- 0001061983
- Website
- cytokinetics.com
- Similar Companies
- Business
- Cytokinetics, Incorporated (Nasdaq: CYTK) is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating cardiovascular and neuromuscular diseases in which muscle performance is compromised or declining; its lead candidate, aficamten, a next-in-class cardiac myosin inhibitor, advances in Phase 3 clinical trials for obstructive hypertrophic cardiomyopathy (oHCM, including monotherapy versus standard of care), pediatric oHCM, and non-obstructive HCM (nHCM), with additional Phase 2 development for heart failure with preserved ejection fraction (HFpEF) under the name ulacamten (CK-586); omecamtiv mecarbil, a cardiac myosin activator, progresses in Phase 3 for heart failure with reduced ejection fraction (HFrEF); the neuromuscular pipeline features CK-089, a fast skeletal muscle troponin activator, alongside additional skeletal muscle activators in research; and broader muscle biology-directed research targets energetics, growth, and metabolism of muscle. The company, founded in 1997 by pioneers in muscle biology and headquartered in South San Francisco, California, operates primarily in the United States with international partnerships extending to Greater China, Japan, and other regions through strategic alliances. Recent developments include a proposed $550 million private placement of convertible senior notes due 2031 in September 2025 to fund aficamten's potential commercial launch, expanded development, pipeline advancement, and debt refinancing; an expanded royalty financing agreement with Royalty Pharma providing up to $575 million, including $250 million upfront, to support aficamten commercialization and omecamtiv mecarbil's Phase 3 studies; and Sanofi's December 2024 acquisition of Corxel Pharmaceuticals' aficamten rights in Greater China, preserving Cytokinetics' eligibility for up to $150 million in milestones and low-to-high teen royalties on sales there.
Company News
Contrasting Actinium Pharmaceuticals (NYSE:ATNM) and Cytokinetics (NASDAQ:CYTK)
Cytokinetics to Announce Third Quarter Results on November 4, 2026
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:TSM)
Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) and Cytokinetics (NASDAQ:CYTK)
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
Analyzing Zai Lab (NASDAQ:ZLAB) and Cytokinetics (NASDAQ:CYTK)
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 3,500 Shares of Stock
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Robert Blum Sells 97,926 Shares of Cytokinetics (NASDAQ:CYTK) Stock
Cytokinetics, Incorporated (CYTK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet
Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program
Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript